@article{3056716,
    title = "SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival",
    author = "Mohelnikova-Duchonova, B. and Strouhal, O. and Hughes, D.J. and Holcatova, I. and Oliverius, M. and Kala, Z. and Campa, D. and Rizzato, C. and Canzian, F. and Pezzilli, R. and Talar-Wojnarowska, R. and Malecka-Panas, E. and Sperti, C. and Federico Zambon, C. and Pedrazzoli, S. and Fogar, P. and Milanetto, A.C. and Capurso, G. and Delle Fave, G. and Valente, R. and Gazouli, M. and Malleo, G. and Teresa Lawlor, R. and Strobel, O. and Hackert, T. and Giese, N. and Vodicka, P. and Vodickova, L. and Landi, S. and Tavano, F. and Gioffreda, D. and Piepoli, A. and Pazienza, V. and Mambrini, A. and Pedata, M. and Cantore, M. and Bambi, F. and Ermini, S. and Funel, N. and Lemstrova, R. and Soucek, P.",
    journal = "Scientific Reports",
    year = "2017",
    volume = "7",
    publisher = "Nature Publishing Group",
    issn = "2045-2322",
    doi = "10.1038/srep43812",
    keywords = "organic cation transporter;  solute carrier family 22 (organic cation transporter), member 3, adult;  aged;  enhancer region;  female;  genetic predisposition;  genetics;  human;  Kaplan Meier method;  male;  middle aged;  pancreas carcinoma;  pancreas tumor;  pathology;  prognosis;  risk factor;  single nucleotide polymorphism, Adult;  Aged;  Carcinoma, Pancreatic Ductal;  Enhancer Elements, Genetic;  Female;  Genetic Predisposition to Disease;  Humans;  Kaplan-Meier Estimate;  Male;  Middle Aged;  Organic Cation Transport Proteins;  Pancreatic Neoplasms;  Polymorphism, Single Nucleotide;  Prognosis;  Risk Factors",
    abstract = "Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were successfully evaluated in the discovery phase while six significant or suggestive variants entered the validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic cancer risk. Moreover, rs7758229 associated with the presence of distant metastases, while rs512077 and rs2504956 correlated with overall survival of patients. Although replicated, the association for rs9364554 did not pass multiple testing corrections in the validation phase. Contrary to the discovery stage, rs2504938 associated with survival in the validation cohort, which was more pronounced in stage IV patients. In conclusion, common variation in the SLC22A3 gene is unlikely to significantly contribute to pancreatic cancer risk. The rs2504938 SNP in SLC22A3 significantly associates with an unfavorable prognosis of pancreatic cancer patients. Further investigation of this SNP effect on the molecular and clinical phenotype is warranted. © 2017 The Author(s)."
}